President Donald Trump revealed a major new agreement Thursday aimed at making the country’s most in-demand weight loss medications dramatically cheaper for millions of Americans.
Speaking from the Oval Office, Trump announced that pharmaceutical giants Eli Lilly and Novo Nordisk… makers of Zepbound, Ozempic and Wegovy… have agreed to slash prices on their GLP-1 weight loss drugs for eligible consumers enrolled in Medicare, Medicaid, and soon, the new “TrumpRx” online prescription platform launching later this year.
According to officials, instead of paying up to $1,350 monthly for these injections, qualifying Americans will soon be able to get them for roughly $245 to $350 a month.
“It wasn’t easy negotiating with these companies… trust me,” Trump said. HHS Secretary Robert F. Kennedy Jr. also revealed that these talks lasted months before both sides finally reached a deal.
As part of the agreement, Eli Lilly and Novo Nordisk will also make their other medications available at “most-favored-nation pricing,” ensuring U.S. customers will be able to pay competitive pricing more aligned with what other countries receive internationally.
The Oval Office announcement briefly paused when one of the company officials suddenly fainted, but the White House says the individual is safe and doing well after immediate medical attention.
The new TrumpRx program… expected to be live before the end of the year… will allow Americans to purchase prescription drugs directly from manufacturers without going through insurance.
Once live, Trump administration officials say injections of Ozempic and Wegovy sold through TrumpRx will average around $350 per month, with the new pricing officially activating in January.
